Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.53 - $60.81
Previous CloseN/A
Volume110.15K
Average Volume (3M)734.71K
Market Cap
$535.60M
Enterprise Value$383.64M
Total Cash (Recent Filing)$229.34M
Total Debt (Recent Filing)$12.04M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 11, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding40,636,982
10 Day Avg. Volume563,212
30 Day Avg. Volume734,706
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.90
Price to Sales (P/S)0.00
P/FCF Ratio-5.72
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda-3.52
Forecast
1Y Price Target
$22.56Price Target Upside70.52% Upside
Rating ConsensusHold
Number of Analyst Covering9
RxSight News
See All RXST News
Bulls Say, Bears Say
Bulls Say
International ExpansionInternational markets represent a significant opportunity for RXST, with plans to enter European and Asian markets where the advanced technology IOL market is twice the size of the US market.
Regulatory ApprovalsRXST highlighted receiving regulatory approval for products in South Korea and expects approval in the UK soon.
ValuationRXST's valuation appears very attractive, trading at a significant discount to its peers, with above-average growth, a strong moat, and high gross margins.
Bears Say
CompetitionCompetition and consumer confidence are risks as other companies are launching competing AT-IOLs in the US, potentially impacting RXST’s growth.
Revenue MissRXST reported 1Q25 revenue of $37.9M, which was below initial consensus estimates by around 4.7%.
Utilization DeclineFor the first time as a public company, RXST saw utilization fall year over year in Q1.
Ownership Overview
5.52% Insiders
19.15% Mutual Funds
36.11% Other Institutional Investors
19.63% Public Companies and Individual Investors
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $12.53 and its highest was $60.81 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $535.60M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Aug 11, 2025 which is in 44 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on May 07, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.217 by $0.017.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.17.
How many shares outstanding does RxSight have?
RxSight has 40,636,982 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.217. Following the earnings report the stock price went down -11.208%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
RxSight Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.56 (70.52% Upside)
$22.56 (70.52% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 447.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 28.7%
Last 30 Days ▲ 28.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.84%
12-Months-Change
Fundamentals
Return on Equity
-11.98%
Trailing 12-Months
Asset Growth
70.91%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed strong revenue growth and customer satisfaction but was overshadowed by the revision of revenue guidance due to macroeconomic challenges and market competition. While European regulatory approval presents a long-term opportunity, short-term challenges persist, affecting performance and outlook.Read More>RXST Stock 12 Month Forecast
Average Price Target
$22.56
▲(70.52%Upside)